{"schema_version":"secwatch.filing_event.v1","accession":"0001510964-22-000065","form_type":"8-K","ticker":"CVSI","cik":"0001510964","company_name":"CV Sciences, Inc.","filed_at":"2022-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.977438+00:00","generated_at":"2026-06-23T23:49:08.052824+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CV Sciences Q2 2022 revenue falls 19% to $4.1M; gross margin drops to 30.7%","bullets":["Revenue $4.1M down from $5.1M YoY; units sold decreased 5%.","Gross margin 30.7% vs 44.7% in Q2 2021, hurt by product mix and higher discounts.","Operating loss narrowed to $2.3M from $3.5M; adj. EBITDA loss $1.8M (vs $2.4M).","Cash balance $1.1M at quarter end; OPEX reduced 38.2% YoY.","Regained top hemp extract brand in natural retail per SPINS; strategic review ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001510964-22-000065","json":"https://secwatch.observer/filing/0001510964-22-000065.json","markdown":"https://secwatch.observer/filing/0001510964-22-000065.md","text":"https://secwatch.observer/filing/0001510964-22-000065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1510964/000151096422000065/0001510964-22-000065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1510964/000151096422000065/cvsi-20220815.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T23:49:08.052824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}